Related Experiment Video
Updated: Oct 3, 2025
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study
K R Campanholo1, M S Pitombeira1, C M Rimkus2
1Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; Department of Neurology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Background:
Cognitive impairment is one of the concerns of Multiple Sclerosis (MS) and has been related to myelin loss. Different neuroimaging methods have been used to quantify myelin and relate it to cognitive dysfunctions, among them Magnetization Transfer Ratio (MTR), Diffusion Tensor Imaging (DTI), and, more recently, Positron Emission Tomography (PET) with 11C-PIB.
Objective:
To investigate different myelin imaging modalities as predictors of cognitive dysfunction.
Methods:
Fifty-one MS patients and 24 healthy controls underwent clinical and neuropsychological assessment and MTR, DTI (Axial Diffusion-AD and Fractional Anisotropy-FA maps), and 11C-PIB PET images in a PET/MR hybrid system.
Results:
MTR and DTI(FA) differed in patients with or without cognitive impairment. There was an association of DTI(FA) and DTI(AD) with cognition and psychomotor speed for progressive MS, and of 11C-PIB uptake and MTR for relapsing-remitting MS. MTR in the Thalamus (β= -0.51, p = 0.021) and Corpus Callosum (β= -0.24, p = 0.033) were predictive of cognitive impairment. DTI-FA in the Caudate (β= -26.93, p = 0.006) presented abnormal predictive result.
Conclusion:
Lower myelin content by 11C-PIB uptake was associated with worse cognitive status. MTR was predictive of cognitive impairment in MS.
Insights
Neuroimaging techniques like MTR and 11C-PIB PET can predict cognitive impairment in Multiple Sclerosis (MS) patients. Lower myelin levels correlate with poorer cognitive function and psychomotor speed in MS.
Area of Science:
- Neuroimaging
- Neurology
- Multiple Sclerosis Research
Background:
- Cognitive impairment is a significant concern in Multiple Sclerosis (MS), often linked to myelin loss.
- Various neuroimaging techniques, including Magnetization Transfer Ratio (MTR), Diffusion Tensor Imaging (DTI), and 11C-PIB Positron Emission Tomography (PET), are used to assess myelin integrity.
- These methods aim to correlate myelin quantification with observed cognitive dysfunctions in MS patients.
Purpose of the Study:
- To evaluate the efficacy of different myelin imaging modalities as predictors of cognitive dysfunction in Multiple Sclerosis.
- To compare the utility of MTR, DTI, and 11C-PIB PET in identifying cognitive deficits associated with MS.
Main Methods:
- Fifty-one MS patients and 24 healthy controls underwent comprehensive clinical and neuropsychological assessments.
- Advanced neuroimaging techniques including MTR, DTI (Fractional Anisotropy and Axial Diffusion maps), and 11C-PIB PET were acquired using a hybrid PET/MR system.
- Data analysis focused on identifying differences and associations between imaging metrics and cognitive performance across different MS subtypes.
Main Results:
- Magnetization Transfer Ratio (MTR) and Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) values differed significantly between MS patients with and without cognitive impairment.
- DTI metrics (FA and Axial Diffusion) were associated with cognitive function and psychomotor speed in progressive MS.
- 11C-PIB uptake and MTR showed associations with cognitive status in relapsing-remitting MS.
- MTR in the Thalamus and Corpus Callosum, and DTI-FA in the Caudate nucleus, were identified as significant predictors of cognitive impairment.
Conclusions:
- Reduced myelin content, as indicated by lower 11C-PIB uptake, is associated with worse cognitive status in Multiple Sclerosis.
- Magnetization Transfer Ratio (MTR) serves as a valuable imaging biomarker for predicting cognitive impairment in MS patients.
- Neuroimaging modalities offer promising avenues for understanding and monitoring cognitive decline in MS.
